The combination of anti-PD-1/PD-L1 antibody and fractionated radiation therapy also elicited CD8 + T cell responses that improved local tumor control, long-term survival, and maintenance of protection against tumor rechallenge. The gene discussed is CD274; the disease is neoplasm.